Skip to main content
. Author manuscript; available in PMC: 2009 Apr 10.
Published in final edited form as: Cancer Biomark. 2005;1(4-5):241–250. doi: 10.3233/cbm-2005-14-507

Table 2.

Associations between clinicopathologic and molecular characteristics and CRC recurrence based on tumor stage

Stage II
Stage III
Variable Number of Patients (%)
χ2 P-value Number of Patients (%)
χ2 P-value
Without recurrence 68 (74%) With recurrence 24 (26%) Without recurrence 30 (45%) With recurrence 36 (55%)
Age Group (years)
< 65 29 (43) 14 (58) 0.1854 15 (50) 15 (42) 0.4984
⩾ 65 39 (57) 10 (42) 15 (50) 21 (58)
Gender
Male 45 (66) 17 (71) 0.6757 21 (70) 19 (53) 0.1539
Female 23 (34) 7 (29) 9 (30) 17 (47)
pT component of stage (bowel wall invasion)
pT1 0.0168 0 (0) 1 (3) 0.2893
pT2 8 (27) 4 (11)
pT3 54 (79) 13 (54) 13 (43) 21 (58)
pT4 14 (21) 11 (46) 9 (30) 10 (28)
pN component of stage (nodal involvement)
N0 68 (74%) 24 (26%) 0.7457
N1 18 (60) 23 (64)
N2–3 12 (40) 13 (36)
Tumor location
Colon 51 (75) 19 (79) 0.6808 25 (83) 26 (72) 0.2835
Rectum 17 (25) 5 (21) 5 (17) 10 (28)
Tumor size (cms)
≤ 5 34 (50) 13 (54) 0.7255 21 (70) 25 (69) 0.9610
> 5 34 (50) 11 (46) 9 (30) 11 (31)
Tumor differentiation
Low grade 59 (87) 23 (96) 0.2198 23 (77) 27 (75) 0.8750
High grade 9 (13) 1 (4) 7 (23) 9 (25)
Bcl-2 expression
Low (ISS* < 0.5) 19 (28) 16 (67) 0.0008 15 (50) 19 (53) 0.8221
High (ISS ⩾ 0.5) 49 (72) 8 (33) 15 (50) 17 (47)
Vital status (at follow-up)
Alive 33 (49) 4 (17) < 0.0001 15 (50) 3 (8) < 0.0001
Colon Cancer** 2 (2) 17 (71) 2 (7) 29 (81)
Other*** 33 (49) 3 (12) 13 (43) 4 (11)
*

ISS = Immuno staining score.

**

Dead due to colorectal cancer.

***

Death due to causes other than colorectal cancer or unknown.